Please wait while we load the requested 10-K report or click the link below:
Completed initial two commercial sales of ICELL8™ Single-Cell System - one to a major global pharmaceutical company and the second to the Neural Stem Cell Institute, a not-for-profit organization that specializes in translational therapeutic stem cell research for diseases of the nervous system
Presented results from Genentech, Karolinska Institutet, National Jewish Health, and MD Anderson Cancer Center highlighting ICELL8™ Single-Cell System performance at the Advances in Genome Biology and Technology (“AGBT”) 2016 General Meeting
Signed a supply agreement with BloodCenter of Wisconsin (“BCW”), a not-for-profit organization that specializes in blood services, diagnostic testing, organ, tissue and marrow donation, medical services and leading-edge research, to provide SmartChip™ Real-Time PCR solutions to BCW to perform high-throughput molecular red cell antigen typing of blood donors
Announced publication of BGI data in GigaScience demonstrating utility of ICELL8™ technology for single-cell analysis in cancer research
Raised net proceeds of approximately $15.7 million in a public offering in October
The following information was filed by Wafergen Biosystems, Inc. (WGBS) on Tuesday, March 8, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Wafergen Biosystems, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Wafergen Biosystems, Inc..